Thrombocytopenia is a common problem in cancer patients. Aside from bleeding risk,
thrombocytopenia limits chemotherapy dose and frequency. In evaluating thrombocytopenic …

Lineage-Specific Hematopoietic Growth Factors | New England Journal of Medicine Skip to main
content The New England Journal of Medicine homepage Advanced Search SEARCH …

Chemotherapy-induced thrombocytopenia (CIT) is a common complication of the treatment
of non-hematologic malignancies. Many patient-related variables (eg, age, tumor type …

The molecular pathways involved in the differentiation of hematopoietic progenitors are
unknown. Here we report that chemokine-mediated interactions of megakaryocyte …

Thrombocytopenia developed in some individuals treated with a recombinant
thrombopoietin (TPO), pegylated recombinant human megakaryocyte growth and …

Thrombopoietin (TPO) is the major physiological regulator of platelet production. TPO binds
the TPO receptor, activates JAK and STAT pathways, thus stimulating megakaryocyte growth …

In the two decades since its cloning, thrombopoietin (TPO) has emerged not only as a critical
haematopoietic cytokine, but also serves as a great example of bench‐to‐bedside research …

The study of thrombopoiesis has evolved greatly since an era when platelets were termed
“the dust of the blood,” only about 100 years ago. During this time megakaryocytes were …

Thrombocytopenia is a common medical problem for which the main treatment is platelet
transfusion. Given the increasing use of platelets and the declining donor population …

Although development of first-generation thrombopoietic growth factors (recombinant human
thrombopoietin [TPO] and pegylated recombinant human megakaryocyte growth and …